LCRF Leading Edge Research Grant Program: Apply by March 10, 2026

Deadline: 10-Mar-2026 The Lung Cancer Research Foundation (LCRF) is accepting applications for the Leading Edge Research Grant Program, providing up to $150,000 over two years for innovative lung cancer studies. This grant supports early-to-mid-career investigators focusing on high-impact areas like lung cancer biology, targeted therapies, machine learning, and health disparities. The program follows a two-stage application process, starting with a Letter of Intent (LOI) due by March 10, 2026. The Lung Cancer Research Foundation (LCRF) Leading Edge Research Grant is a competitive funding opportunity designed to support transformative research across the entire lung cancer continuum. By targeting innovative, high-risk, and high-reward projects, the LCRF aims to accelerate the discovery of more effective, less toxic treatments and improve patient outcomes globally. Why It Matters: Advancing the Frontier of Oncology This grant program is critical for bridging the gap between basic science and clinical application. Early-Career Support: It provides vital seed funding for researchers with less than seven years of faculty experience. Multidisciplinary Scope: It funds everything from basic biology to social determinants of health (SDOH), recognizing that lung cancer outcomes are influenced by both genetics and environment. Technological Integration: The program prioritizes the use of cutting-edge tools like machine learning and digital pathology to revolutionize diagnosis and personalized medicine. Key Concepts and Expanded Definitions Translational Research: The process of turning laboratory discoveries into new clinical treatments or diagnostic tools. Biomarkers: Biological molecules found in blood or tissue that indicate the presence of cancer or predict how a patient will respond to a specific treatment. Antibody-Drug Conjugates (ADCs): A class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. Theranostics: A combination of “therapy” and “diagnostics.” It involves using a single radioactive drug to identify (diagnose) and then deliver therapy to treat the cancer. Social Determinants of Health (SDOH): The non-medical factors—such as social, economic, and environmental conditions—that influence health outcomes and disparities in lung cancer. Who is Eligible? LCRF focuses on supporting the next generation of leadership in oncology research. Eligible Applicants: Affiliation: Must be primarily affiliated with a non-profit academic or research institution. Career Stage: Post-doctoral researchers, clinical fellows, and early-to-mid-career investigators. Experience Limit: Less than seven years since the initial faculty appointment. Geography: Open to both US-based and international researchers regardless of citizenship. Ineligibility Criteria: Senior investigators with >7 years of experience (unless serving as mentors). Current LCRF grant recipients or those funded within the last four years. Applicants applying to multiple LCRF tracks in the same cycle. Grant Funding and Allowable Costs Total Award: Maximum of $150,000. Duration: Two years ($75,000 disbursed per year). Indirect Costs: 0%. Institutional indirect or administrative costs are strictly prohibited. Salary Support: Allowed with justification; requests >20% of the budget require detailed explanation. Other Costs: Limited equipment (project-specific), travel, and publication expenses are permitted. How to Apply: The Two-Stage Process The application is managed via Proposal Central and involves a rigorous peer-review process. Stage 1: Letter of Intent (LOI) Specific Aims: A one-page document outlining the project’s goals. Biosketches: Current NIH-format biosketches for the Principal Investigator (PI) and key personnel. Deadline: March 10, 2026. Stage 2: Full Proposal (By Invitation Only) Letter of Support: Documentation from a program director or advisor confirming institutional backing and resources. Evaluation: Assessed based on rationale, feasibility, innovation, and potential for patient impact. Deadline: June 2, 2026. 2026 Timeline and Key Dates LOI Deadline: March 10, 2026 LOI Notification: April 28, 2026 Full Proposal Deadline: June 2, 2026 Award Notification: November 2026 Project Start Date: December 1, 2026 Common Mistakes and Tips Including Indirect Costs: Budgets that include institutional overhead (indirect costs) will be flagged; LCRF only covers direct research costs. Exceeding Salary Caps: If your salary support exceeds 20% of the $75,000 annual disbursement, provide a robust justification to avoid scrutiny. Neglecting the Lay Update: LCRF requires updates for a non-scientific audience. Successful applicants are those who can communicate their research’s impact to patient advocates. Senior Investigator as PI: Senior researchers must act as mentors, not as the primary PI. Ensure the lead applicant meets the <7-year faculty requirement. FAQ: Frequently Asked Questions 1. Can international researchers apply for this grant? Yes. LCRF accepts applications from investigators at non-profit institutions worldwide, regardless of their citizenship or residency status. 2. What is the limit for indirect costs? LCRF does not allow any funds to be used for indirect, administrative, or overhead costs. 100% of the grant must go toward direct project expenses. 3. Is there a specific format for the Letter of Intent? Yes. The Specific Aims must be a maximum of one page and follow the formatting guidelines provided on Proposal Central. 4. Can I apply if I was funded by LCRF five years ago? Yes. The restriction applies to those who have received LCRF funding within the past four years. 5. How is the second year of funding secured? Continuation of funding for the second year depends on the approval of an interim scientific report submitted at the end of Year 1. 6. Are patient advocates involved in the review? Yes. Applications undergo a three-part review: administrative, scientific peer review, and a review by patient advocates to assess the project’s relevance to the patient community. 7. Does the grant support telemedicine or palliative care research? Yes. The “supportive care” priority area explicitly includes telemedicine, palliative care, and social determinants of health. Conclusion The LCRF Leading Edge Research Grant represents a significant investment in the future of lung cancer treatment. By prioritizing early-career innovation and a holistic approach to cancer biology, LCRF empowers researchers to explore metabolic vulnerabilities and novel bioengineering solutions. Strict adherence to the two-stage application process and a focus on “high-impact” science are essential for a successful submission.